Compass Biotechnologies Inc (COBI: OB) announces its subsidiary company C-Pharma to focus on Hepatitis Franchise while Compass focuses on Biosimiliar and Bio-Better near term revenue products

EDMONTON, April 8 /PRNewswire/ - Compass Biotechnologies (COBI:OB)(formerly Cyplasin Biomedical (CPBM: OTCBB and XYI1:FRA) had previously announced on March 29 that it undergone a name and symbol change. The name change was a first step in a corporate re focusing that would allow the Hepatitis C project to continue as originally envisioned sheltered within C-Pharma Inc., and to allow its parent company Compass Biotechnology to take advantage of several exciting opportunities within the generic biosimiliar and bio better markets.

Garth Likes CEO of Compass commented "we have given this strategy a lot of thought and came to the conclusion that in order to keep the development of our Hepatitis C products and vaccines as a prime focus but yet to increase share holder value we should apply our product development knowledge and experience to other opportunities as well and thus chose the biosimiliar and bio better market areas. We are very excited about various prospects that we are working on and hope to announce some of these shortly."

Joseph Sinkule a Director of the Company stated "bio-betters," are essentially second generation biologics drugs that can be reformulated to perform better than the original drug. It's a simple strategy: find a new biologic that is safer and more effective than a top earner already on the market -perhaps delivered more easily for greater compliance- and you have a potential billion-dollar therapy on your hands."

For the venture backers, one of the chief attractions of these bio-better programs is that they offer a classic de-risking for their investors. If you know the technology and you've seen how it works in the clinic then by reformulating it to be a little better in some fashion gives you a better shot at goal. Bio-betters however can still require long and expensive clinical trial programs, which are not entirely risk free. The Company will also need to make sure that the new therapies offer a significant advantage over anything on the market as we do not want to develop generic me too drugs, but products with intellectual property rights and patents.

Mr. Likes went on to say that that the company is still catching up with the creation of a new web site for Compass Biotechnologies and hopes to have this up shortly.  In the meantime interested persons can still go to www.c-pharma.net

ABOUT COMPASS BIOTECHNOLOGIES INC.

Compass Biotechnologies (formerly Cyplasin Biomedical) is a publically-traded specialty pharmaceutical company (COBI:OB) with headquarters in Edmonton, Alberta. The mission of Compass is to develop new and exciting biosimiliar and bio better drug products that can bring revenue generation to the company in a near term fashion. Further the Compass under it license from the National Institutes of Health (NIH) has opportunities to develop products from the platform technology available and or sub licensee these opportunities to other interested partners.

Compass Biotech also owns a subsidiary company called C-Pharma Inc.

ABOUT C-PHARMA INC.

C-Pharma 's technology encompasses the use of recombinant DNA technology to manufacture virus like particles (VLPs).  These VLPs can be engineered to incorporate various viral and non-viral antigens for use as vaccines against many different types of targets such as Hepatitis C.  The recombinant antigens presented in the context of a VLP carrier system are much more immunogenic than the antigen alone, and this carrier is so powerful that the subsequent vaccine may not require the use of immune adjuvants. Cyplasin is using the technology to develop a Hepatitis C vaccine to prevent hepatitis C viral infection of liver hepatocytes. The Company is also pursuing a revenue generation strategy by commercializing generic therapeutic drugs for use in the Hepatitis C market.

Forward Looking Statements
This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Statements in this current report which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. 

Actual results could differ from those projected in any forward-looking statements due to numerous factors.  Such factors include, among others, the inherent uncertainty of financial estimates and projections, the competitive and regulatory environments, stock market conditions, unforeseen technical difficulties and our ongoing ability to operate a business and obtain financing.  These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. 

Although we believe that our beliefs, plans, expectations and intentions contained in this current report are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.  Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our quarterly reports on Form 10-Q and our other periodic reports filed from time-to-time with the Securities and Exchange Commission pursuant to the Securities Exchange Act.

SOURCE Cyplasin Biomedical Ltd.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED